LATAM Daily Brief
SEE OTHER BRANDS

Following the news from Latin America

LATAM Daily Brief: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on LATAM Daily Brief.

Press releases published on May 8, 2025

KMT-Hansa Enters Into Memorandum of Understanding

KMT-Hansa Enters Into Memorandum of Understanding

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- KMT-Hansa Corp. (the “Company”) is pleased to announce that it has entered into a memorandum of understanding (the “MOU”) with Astra Algorithm Limited (“Astra”), an arm’s length party to the Company. Astra is a …

Bitget Wallet Launches Full Support for Sei Network, Announces $700K Ecosystem Initiative

Bitget Wallet Launches Full Support for Sei Network, Announces $700K Ecosystem Initiative

SAN SALVADOR, El Salvador, May 08, 2025 (GLOBE NEWSWIRE) -- Bitget Wallet, a leading Web3 non-custodial wallet, now offers full support for the Sei network — expanding its multi-chain capabilities and making it easier for users globally to access and …

BBT: The World’s First Crypto Project Realizing Trump’s ‘Baby Bonus’

BBT: The World’s First Crypto Project Realizing Trump’s ‘Baby Bonus’

- BabyBoomToken (BBT), the AI-driven crypto tackling low birth rates, expands into South Korea - Backed by Elon Musk’s warnings and Trump’s policy vision, BBT leads a new era of population-focused tokens Donald Trump lifts a baby during a campaign rally in …

Evolving Systems' Smart Dealer Powers Smarter Dealer Management with Five Integrated Modules

Evolving Systems' Smart Dealer Powers Smarter Dealer Management with Five Integrated Modules

Optimize dealer operations, gain real-time performance insights, and scale your telecom sales network with a platform built for multi-channel success. MANCHESTER, UNITED KINGDOM, May 8, 2025 /⁨EINPresswire.com⁩/ -- As telecom operators navigate …

Veru Participates in a Virtual Investor KOL Connect Segment

Veru Participates in a Virtual Investor KOL Connect Segment

-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage …

Red Cat to Report Q1 2025 Earnings and Provide Corporate Update on Wednesday, May 14, 2025

Red Cat to Report Q1 2025 Earnings and Provide Corporate Update on Wednesday, May 14, 2025

SAN JUAN, Puerto Rico, May 08, 2025 (GLOBE NEWSWIRE) -- Red Cat (Nasdaq: RCAT) ("Red Cat" or the "Company"), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, announces that financial …

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM’s drug Ampligen by Pawel Kalinski, MD, PhD, at the recent …

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over …

HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025

HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025

Prof. Lars Zender’s featured talk described HepaRegeniX’s lead candidate and its potential in increasing liver regeneration, from initial target discovery and drug development towards Phase Ia clinical trial results Tuebingen, Germany, May 8, 2025 – …

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R…

MEXC Lists Doodles (DOOD) with 50,000 USDT Worth of DOOD and 50,000 USDT Bonus Prize Pool

MEXC Lists Doodles (DOOD) with 50,000 USDT Worth of DOOD and 50,000 USDT Bonus Prize Pool

VICTORIA, Seychelles, May 08, 2025 (GLOBE NEWSWIRE) -- MEXC, a leading global cryptocurrency exchange, announces it will list Doodles (DOOD) on May 9, 2025 (UTC). To celebrate this significant addition to the exchange, MEXC is launching a special event …

Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025

Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to treating the core symptoms of autism spectrum disorder (ASD), today announced positive Phase 2 results for L1-79, presented at the …

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

PRINCETON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and infectious …

ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)

ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)

Approximately 15 million USD Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases Oryzon will explore Aggression in specific subsets of Autism Spectrum Disorder (ASD) to expand the precision …

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a …

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

Worldwide first artificial Human Platelet Lysate (HPL) solution – a key ingredient for the research …

Pasinex Announces Issuance of Failure to File Cease Trade Order

Pasinex Announces Issuance of Failure to File Cease Trade Order

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Pasinex Resources Limited (CSE: PSE) (FSE: PNX) ("Pasinex" or the "Company") today announced that the British Columbia Securities Commission, as its principal regulator, has issued a Failure to File Cease Trade …

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the …

American Tungsten Corp. Announces Addition to Board of Directors

American Tungsten Corp. Announces Addition to Board of Directors

Vancouver, BC, May 08, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) announces today the appointment of James (Jim) Whittaker to the Board of Directors of the Company (the “Board …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service